Christy M. Finke

Mayo Clinic — United States

Medicine · Health Sciences

67h-index15.7kcitations456works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(222), Acute Myeloid Leukemia Research(214), Chronic Myeloid Leukemia Treatments(91), Cancer Mechanisms and Therapy(78), Peptidase Inhibition and Analysis(74)

Publications456 total

Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia
Blood Cancer Discovery·2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.
Blood Advances·2026· 1 citedOpen Access
Inherited DNA repair variants are associated with clonal hematopoiesis and cardiovascular risk in men with metastatic prostate cancer
Haematologica·2025Open Access
Supplementary Figure S4 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S7 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S6 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S5 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Figure S5 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Table S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
Figure S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
2025Open Access
page 1 of 23Next →

Frequent Co-authors

Terra L. Lasho(48), Ayalew Tefferi(47), Animesh Pardanani(45), Curtis A. Hanson(34), Rhett P. Ketterling(31), Naseema Gangat(23), Mrinal M. Patnaik(16), Ryan A. Knudson(12), Paola Guglielmelli(10), Alessandro M. Vannucchi(9), Emnet A Wassie(8), Alem A. Belachew(7), Kebede H. Begna(7), Giada Rotunno(5), Rebecca R. Laborde(5), Rebecca F. McClure(5), Thitina Jimma(5), Alessandro Pancrazzi(4), Domenica Caramazza(4), Mythri Mudireddy(4)